secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2024-09-26T23:59:59+00:00
Accession:  0001437749-24-030075
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma FY2024 revenue $81M, adjusted EBITDA $9.2M; ADHD net revenue +23%
--------------------------------------------------------------------------------

- FY2024 consolidated net revenue $81.0M (down 25% YoY); net loss $15.8M ($2.86/share)
- Adjusted EBITDA improved to $9.2M from $3.5M ( +162%); Rx Business EBITDA $10.8M
- ADHD Portfolio net revenue +23% to $57.8M; Pediatric unit shipments up 115% since July 1
- Consumer Health Segment divested in July 2024; company expects Rx Segment revenue and EBITDA growth in FY2025
- Cash balance $20.0M; refinanced term loan; $3.5M from warrant exercises

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000143774924030075/0001437749-24-030075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000143774924030075/aytu20240610_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-030075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer